Revance Therapeutics, Inc.
US ˙ NasdaqGM ˙ US7613301099
DETTE SYMBOL ER IKKE LÆNGERE AKTIVT

SecurityRVNC / Revance Therapeutics, Inc.
InstitutionGhost Tree Capital, LLC
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Ghost Tree Capital, LLC closes position in RVNC / Revance Therapeutics, Inc.

On November 14, 2024 - Ghost Tree Capital, LLC filed a 13F-HR form disclosing ownership of 0 shares of Revance Therapeutics, Inc. (US:RVNC) valued at $0 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 14, 2024 disclosing 225,000 shares of Revance Therapeutics, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2024-11-14 2024-09-30 13F REVANCE THERAPEUTICS COM 761330109 0 -225,000 -100.00 0 -100.00
2024-08-14 2024-06-30 13F REVANCE THERAPEUTICS COM 761330109 225,000 -225,000 -50.00 578 -73.89 0.1811
2024-05-15 2024-03-31 13F REVANCE THERAPEUTICS COM 761330109 450,000 75,000 20.00 2,214 -32.83 0.6128
2024-02-14 2023-12-31 13F REVANCE THERAPEUTICS COM 761330109 375,000 25,000 7.14 3,296 -17.89 1.0777
2023-11-14 2023-09-30 13F REVANCE THERAPEUTICS COM 761330109 350,000 -175,000 -33.33 4,014 -69.79 1.3203
2023-08-14 2023-06-30 13F REVANCE THERAPEUTICS COM 761330109 525,000 275,000 110.00 13,288 64.99 4.3866
2023-05-15 2023-03-31 13F REVANCE THERAPEUTICS COM 761330109 250,000 -50,000 -16.67 8,053 45.41 2.3803
2023-02-14 2022-12-31 13F REVANCE THERAPEUTICS COM 761330109 300,000 -90,000 -23.08 5,538 -47.41 2.3644
2022-11-14 2022-09-30 13F REVANCE THERAPEUTICS COM 761330109 390,000 390,000 10,530 2.9557
2017-11-14 2017-09-30 13F REVANCE THERAPEUTICS COM 761330109 0 -89,295 -100.00 0 -100.00
2017-08-14 2017-06-30 13F REVANCE THERAPEUTICS COM 761330109 89,295 89,295 2,357 0.4899
2015-08-14 2015-06-30 13F REVANCE THERAPEUTICS COM 761330109 0 -200,000 -100.00 0 -100.00
2015-05-15 2015-03-31 13F/A-1 REVANCE THERAPEUTICS COM 761330109 200,000 200,000 4,146 1.4909
2015-05-15 2015-03-31 13F REVANCE THERAPEUTICS COM 761330109 200,000 0 4,146
2014-11-14 2014-09-30 13F REVANCE THERAPEUTICS COM 761330109 0 -20,000 -100.00 0 -100.00
2014-08-14 2014-06-30 13F REVANCE THERAPEUTICS COM 761330109 20,000 0 0.00 680 7.94 0.4796
2014-05-15 2014-03-31 13F REVANCE THERAPEUTICS COM 761330109 20,000 20,000 630 0.3741
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.